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This study examined factors associated with persistence (time from initiation to discontinuation of treatment) on
initial antiretroviral (ARV) therapy in commercially insured HIV patients in the United States, a population not
well researched. This retrospective analysis of US health insurance claims data from 1 January 2003 to 30 June
2008 included treatment-naive patients aged 1865 years with an HIV diagnosis receiving ARV therapy
consisting of at least two individual nucleoside reverse transcriptase inhibitors (NRTIs) or one fixed-dose
combination NRTI, plus at least one nonnucleoside reverse transcriptase inhibitor (NNRTI) or one protease
inhibitor (PI), with or without ritonavir. Descriptive statistics, Kaplan-Meier survival estimation, and Cox
proportional hazards regression models were completed. Patients were considered persistent until any component
of the regimen was modified or there was a gap in treatment  90 days. A total of 2460 patients met full inclusion
criteria (1388 NNRTI and 1072 PI). Mean (SD) time to discontinuation for NNRTI- vs PI-based regimens was
370 (346) vs 295 (338) days (pB0.001). Female sex, substance use, low comorbidity score, index year before 2007,
geographical region, and taking a lopinavir/ritonavir regimen predicted discontinuation. Relative to NNRTI-
based regimens, PI-based regimens demonstrated a greater risk of discontinuation (hazard ratio [HR], 1.32;
pB0.001). The fixed-dose efavirenz/emtricitabine/tenofovir combination yielded the lowest risk of discontinua-
tion (HR, 0.39; pB0.001). HIV treatment persistence was longer with NNRTI-based regimens than PI-based
regimens. The fixed-dose regimen of once-daily efavirenz/emtricitabine/tenofovir had the lowest risk of
discontinuation.
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Introduction
Current US guidelines for the treatment of HIV-1
infection identify four preferred antiretroviral
(ARV) regimens as initial therapy (Panel on Antire-
troviral Guidelines for Adults and Adolescents, 2009).
These regimens comprise agents from four drug
classes: nucleoside reverse transcriptase inhibitors
(NRTIs), nonnucleoside reverse transcriptase inhibi-
tors (NNRTIs), ritonavir-boosted protease inhibitors
(PIs), and integrase inhibitors. The current treatment
paradigm calls for lifelong ARV therapy in HIV-
infected individuals. Though much has been published
on the efficacy of the currently preferred initial regi-
mens, few studies have explored HIV ARV treatment
persistence.
Persistence is defined as the duration of pharma-
cological treatment, from initiation to discontinuation
(Cramer et al., 2008). This is operationally distinct
from adherence, which indicates the extent to which a
patient abides by the prescribed treatment regimen in
terms of dose,frequency, andtiming of administration
(Cramer et al., 2008). Persistence is measured by the
number of days taking medication without exceeding
a permissible gap. Persistence is an important concept
in HIV management as patients are likely to remain
on lifelong ARV therapy, and the discontinuation
of an ARV regimen, if associated with virological
failure, may represent a permanent loss of therapeutic
options.
HIV treatment persistence may be affected by a
number of characteristics of the patient and the
treatment regimen. Patient-related factors that may
be associated with shorter persistence include disease
severity (Ahdieh-Grant et al., 2005; Li et al., 2005;
Mocroft et al., 2001; van Roon et al., 1999), younger
age (Crystal, Sambamoorthi, Moynihan, & McSpiritt,
2001; Li et al., 2005; Mocroft et al., 2001), and female
sex(Spire, Carrieri, Garzot, L’henaff, & Obadia,
2004). Treatment regimen characteristics associated
with shorter persistence include efficacy, tolerability
profile, and regimen complexity (e.g., higher pill
burden and dosing frequency; Panel on Antiretroviral
Guidelines for Adults and Adolescents, 2009; Elzi
et al., 2010). The introduction of NNRTI-based
treatment regimens; the arrival of new fixed-dosed
NRTI combinations; a trend toward lower pill
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of the one-pill, once-a-day ARV regimen of
efavirenz/emtricitabine/tenofovir (EFV/FTC/TDF)
have greatly simplified HIV treatment by allowing
for lower pill burden, once-daily dosing, and longer
treatment persistence (Willig et al., 2008).
Few studies on persistence have been completed in
select HIV-infected populations, and little is known
about the factors influencing treatment persistence
in privately insured patients living with HIV/AIDS.
Much of the available data on patients with HIV
infection are from studies carried out in university
clinics and resource-limited settings. Our analysis
provides much-needed data on the factors associated
with ARV therapy persistence in privately insured
patients, a group estimated to represent 31% of HIV-
infected adults in the United States (Board on Health
Promotion and Disease Prevention [HPDP], 2005).
More specifically, we were interested in assessing if
the factors driving persistence in commercially in-
sured patients are similar to those seen in published
cohort studies.
Using medical and prescription claims data from
a large US commercial claims database, we examined
persistence in commercially insured patients on initial
ARV therapy. The objectives of the analysis were to:
(1) compare the rates of persistence between NNRTI-
and PI-containing regimens, (2) assess the factors
associated with risk of treatment discontinuation, and
(3) compare the risk for discontinuation of specific
ARV regimens.
Methods
Study population and data collection
This retrospective cohort study used medical and
prescription claims data from the PharMetrics
Integrated Outcomes Database for the period from
1 January 2003 to 30 June 2008. The PharMetrics
Integrated Database is a de-identified, integrated
claims database of commercial insurers that contains
patient demographics, health insurance coverage, and
medical andpharmacyclaims for morethan55 million
unique members from 75 health plans across
the United States (http://www.imshealth.com). The
patients in the database are representative of the
national commercially insured US population in
terms of age, sex, and type of health plan with an
approximate distribution of health plan type:
preferred provider organization (52%), health
maintenance organization (20%), point-of-service
(18%), indemnity (7%), and other/unknown (3%).
The representativeness of the database enhances the
generalizability of study results.
Figure 1 details the study’s inclusion and exclu-
sion criteria. Patients were required to be aged 1865
years, to have at least one medical claim with an
International Classification of Diseases Ninth Edition
Figure 1. Selection of patients with an HIV diagnosis who initiated ARV therapy involving a minimum of two NRTIs plus
one NNRTI or one PI (9 ritonavir); ARV, antiretroviral; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI,
nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
AIDS Care 1155(ICD-9) diagnosis code for HIV infection (AIDS
[042], HIV disease [042], symptomatic HIV infection
[042], nonspecific serological evidence of HIV
[795.71], or asymptomatic HIV infection [V08])
between 1 January 2003 and 30 June 2008, and to
have initiated a prescription for an ARV regimen
containing a minimum of three drugs including at
least two NRTIs and one NNRTI or PI (/
ritonavir [r]) between 1 July 2003 and 30 December
2007. Exclusion criteria included an ICD-9 diagnostic
or service code for pregnancy. The integrase inhibitor
raltegravir was not included in the analysis because it
was not approved for treatment-naive patients until
July 2009 or recommended by treatment guidelines
for initial therapy until December 2009. The first
claim for an ARV regimen was considered a patient’s
indexdate. Patients were designated as treatment
naive and starting initial ARV therapy if no ARV
prescriptions were present for at least sixmonths (180
days) prior to the indexdate. As shown in Figure 2,
patients were required to be enrolled in the claims
database for at least sixmonths prior to and six
months after the indexdate. Patients were followed
until they met the study-defined criteria for nonper-
sistence described below.
This study was conducted in accordance with the
ethical principles of the Declaration of Helsinki. The
de-identified data-set in this study was compliant with
all requirements of the Health Insurance Portability
and Accountability Act (HIPAA).
Independent variables
Table 1 presents a list of the regimens used by patients
in the main analyses. Regimen covariates included
treatment category (NNRTI-based regimen vs PI-
based regimen) and regimen type as defined by a
specific third agent used in the regimen. In addition,
use of fixed-dose combinations (FDCs)  i.e., EFV/
FTC/TDF, tenofovir/emtricitabine (TDF/FTC),
abacavir/lamivudine (ABC/3TC), zidovudine/lamivu-
dine (AZT/3TC), zidovudine/lamivudine/abacavir
(AZT/3TC/ABC), and lopinavir/ritonavir (LPV/r) 
was included as a regimen covariate.
Patient covariates included age, sex, geographical
region (Northeast, Midwest, South, West), total daily
pills of non-ARV treatment, Charlson Comorbidity
Indexscores, calendar year at indexdate for regimen
initiation, and psychiatric and substance abuse co-
morbidities per corresponding ICD-9 diagnostic
codes.CharlsonComorbidityIndexscores(aweighted
summary score based on the presence or absence of
17 medical conditions where higher scores indicate a
greater burden of comorbidity; Charlson, Pompei,
Ales, & MacKenzie, 1987) were calculated for each
patient after identifying comorbidities using ICD-9
diagnostic codes for the 17 associated conditions.
Outcome measures
The primary outcome measure was persistence (time
to discontinuation) of the first-line ARV regimen.
Participants were considered to be persistent until any
component of the regimen was modified (including
discontinuation of or addition of an ARV medica-
tion) or there was a gap in treatment  90 days.
Treatment gaps (interruptions in pharmacy refill
data) of  90 days were considered regimen disconti-
nuations. A permissible gap of B90 days was chosen
for this study to ensure that patients deemed
nonpersistent had actually discontinued treatment.
Transitions to a new fixed-dose combination (e.g.,
EFVFTC/TDF to EFV/FTC/TDF) were censored
and not counted as regimen modification.
Statistical analyses
All statistical analyses were conducted using SAS
version 9.1 (SAS Institute Inc., Cary, NC). The
p-value for statistical significance was 0.05.
Figure 2. Study schematic.
1The indexdate occurred between July 2003 and December 2007;
2The ARV regimen involved a
minimum of two NRTIs plus one NNRTI or one PI (9 ritonavir);
3Nonpersistence was deﬁned as discontinuation of the
ARV regimen following an allowed 90-day gap between reﬁlls or any change to the initial ARV regimen prescribed; ARV,
antiretroviral; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI,
protease inhibitor.
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containing treatment cohorts. Descriptive statistics
included bivariate statistics to assess the distribution
of characteristics in the two cohorts. Bivariate
analyses were conducted using t tests for continuous
variables and x
2 tests for categorical variables.
Kaplan-Meier survival estimation was used to
examine time to persistence (time to discontinuation)
by treatment category (NNRTI vs PI). A Cox
proportional hazards regression model was used to
assess multivariate risk of regimen discontinuation.
This model was used to compare treatment category
(NNRTI vs PI) and to compare more detailed regi-
men and patient characteristics.
A subanalysis used a Coxproportional hazards
regression model to assess multivariate risk of
discontinuation of specific first-line regimens in
common use vs the EFV/FTC/TDF fixed-dose regi-
men. These regimens included: LPV/rAZT/3TC,
LPV/rTDF/FTC, EFVAZT/3TC, ATV/rTDF/
FTC, and EFVTDF/FTC (excluding EFV/FTC/
TDF). For a specific treatment regimen to be included
in this subanalysis, at least 100 patients in the analytic
sample had to be on the regimen.
Sensitivity analyses using permissible treatment
gaps shorter than 90 days (i.e., 14 and 30 days,
respectively) were conducted to assess the robustness
of study results to the duration of permissible
treatment gap.
Results
As shown in Table 2, within the cohort of 2460
patients meeting all study inclusion criteria, 1388
patients were on an NNRTI-based regimen and 1072
were on a PI-based regimen. The NNRTI cohort
contained a significantly higher proportion of men
than the PI cohort (81.7% vs 77.0%, respectively;
p0.004). Those on NNRTI-based regimens were
younger (42.2 vs 43.2 years; p0.004) and had lower
daily pill burden (4.0 vs 9.5; pB0.0001) when
compared with those on PI-based regimens. The
proportion of patients using a fixed-dose combina-
tion as part of their indexregimen was comparable
between NNRTI- and PI-treated groups (72.7% vs
73.4%, respectively; p0.69). Pre-indexCharlson
Comorbidity Indexscores were identical for both
treatment groups (6.2). There were no statistically
significant differences in the distribution of substance
abuse, depression, bipolar, and psychotic disorders
between the NNRTI- and PI-based groups.
Overall, 68.2% of NNRTI-treated patients dis-
continued or modified their treatment in the study
period, compared with 78.5% of the PI-treated group
(pB0.0001). In the period between indexdate and
discontinuation, PI-treated patients had a lower
number of prescription refills than their NNRTI
counterparts (mean, 11.9 vs 13.5, respectively;
pB0.001).
Persistence (time to discontinuation) of initial regimen
by drug class
Figure 3 presents the Kaplan-Meier estimation of
persistence (time to discontinuation) for the NNRTI
and PI cohorts. The figure indicates that persistence
was significantly longer in the NNRTI cohort relative
to the PI cohort. The mean (standard deviation [SD])
time to treatment discontinuation in the NNRTI
group was 370 (346) days compared with 295 (338)
days in the PI group (pB0.001; log-rank test). Similar
results were observed in the sensitivity analyses when
permissible treatment gaps of 14 and 30 days were
used to classify regimens as discontinued.
Risk of regimen discontinuation
Table 3 presents the multivariate risk for regimen
discontinuation associated with regimen and patient
factors. Relative to NNRTI-based regimens, PI-based
regimens demonstrated a greater risk of discontinua-
tion (HR, 1.32; pB0.001). There was no association
between use of a fixed-dose combination in the index
regimen and risk of regimen discontinuation during
the observation period (HR, 1.06; p0.345). Analysis
of commonly used indexARV regimens revealed
that the EFV/FTC/TDF fixed-dose regimen was
associated with a significantly lower risk of disconti-
nuation than other regimens (HR, 0.39; pB0.001). In
Table 1. Description of regimens.
Regimen n
NNRTI-based (total) 1388
EFV-containing
a 885
EFV/FTC/TDF fixed-dose 327
Other NNRTI
b 176
PI-based (total) 1072
LPV/r-containing 419
ATV/r-containing 272
Other PI
c 381
All regimens (total) 2460
aExcludes use of the EFV/FTC/TDF fixed-dose regimen.
bOther NNRTI-based regimens were primarily comprised of
regimens containing nevirapine or etravirine.
cOther PI-based regimens were primarily comprised of regimens
containing darunavir, fosamprenavir, or nelfinavir.
Abbreviations: ATV, atazanavir; EFV, efavirenz; FTC, emtri-
citabine; LPV, lopinavir; NNRTI, nonnucleoside reverse tran-
scriptase inhibitor; PI, protease inhibitor; r, ritonavir; TDF,
tenofovir disoproxil fumarate.
AIDS Care 1157Table 2. Characteristics of patients (n2460) included in the study cohort by type of indexantiretroviral regimen (NNRTI
vs PI).
Variable NNRTI PI p-value
a
n1388 n1072
Age, mean (SD) 42.2 (9.4) 43.2 (9.3) 0.004
Male, n (%) 1134 (81.7) 825 (77.0) 0.004
FDC use in indexregimen, n (%) 1009 (72.7) 787 (73.4) 0.690
Total daily pills in indexregimen,
mean (SD)
4.0 (4.6) 9.5 (8.4) B0.0001
Region, n (%) 0.084
b
Northeast 455 (32.8) 369 (34.4)
Midwest 379 (27.3) 303 (28.3)
South 249 (17.9) 209 (19.5)
West 305 (22.0) 191 (17.8)
Pre-indexCharlson Comorbidity
Index, mean (SD)
c
6.24 (2.2) 6.24 (2.3) 0.915
Pre-indexcomorbidity, n (%)
Depression 197 (14.2) 146 (13.6) 0.684
Bipolar disorder 44 (3.2) 50 (4.7) 0.055
Psychotic disorder 13 (0.9) 10 (0.9) 0.992
Substance use disorder 157 (11.3) 144 (13.4) 0.111
Year of indexdate, n (%) 0.012
b
2003 156 (11.2) 129 (12.0)
2004 296 (21.3) 268 (25.0)
2005 290 (20.9) 247 (23.0)
2006 410 (29.5) 288 (26.9)
2007 236 (17.0) 140 (13.1)
ap-value for difference between NNRTI- and PI-based regimens.
bCategorical analysis using x
2 test.
cCharlson Comorbidity Index, a weighted summary score based on the presence or absence of 17 medical conditions.
Abbreviations: FDC, fixed-dose combination; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; SD, standard
deviation.
Figure 3. Persistence (i.e., time to discontinuation) by type of indexARV regimen (NNRTI-based or PI-based). The
difference in time to discontinuation between PI- and NNRTI-based regimens was p B0.0001 (log-rank test); ARV,
antiretroviral; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
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associated with a significantly greater risk of disconti-
nuation than regimens not containing LPV/r (HR,
1.32; pB0.001). Sensitivity analyses using 14- and 30-
day permissible treatment gaps showed similar results.
Patient variables associated with a greater risk of
regimen discontinuation included a pre-indexhistory
of a substance use disorder (HR, 1.30; pB0.001) and
earlier year of indexdate (all years compared with
2007; pB0.001; Table 3). Variables associated with a
lower risk of regimen discontinuation included male
sex(HR, 0.84; p0.005), location in the Midwest
(HR, 0.85; p0.027), or West (HR, 0.69; pB0.001)
compared with the South and higher post-indexand
prediscontinuation Charlson Comorbidity Index
scores (HR, 0.84; pB0.001). Sensitivity analyses
using 14- and 30-day permissible treatment gaps
showed similar results.
Risk of discontinuation of specific regimens
Table 4 presents a subanalysis of the multivariate risk
of discontinuation associated with commonly used
ARV regimens. Compared with fixed-dose EFV/
FTC/TDF, the following regimens were associated
with a greater risk of discontinuation: EFVAZT/
3TC (HR, 1.83; pB0.001), LPV/rTDF/FTC (HR,
2.03; pB0.001), and LPV/rAZT/3TC (HR, 2.33;
pB0.001). Sensitivity analyses using 14- and 30-day
permissible treatment gaps showed similar results.
Discussion
ARV treatment persistence is of paramount impor-
tance as current HIV management requires lifelong
therapy and discontinuation may permanently elim-
inate future treatment options. This analysis provides
rare insight into treatment persistence among com-
mercially insured individuals with HIV infection, an
Table 3. Multivariate risk of regimen discontinuation (n 2460).
Variable Hazard ratio p-value
PI-based vs NNRTI-based 1.32 B0.001
FDC use vs no FDC use 1.06 0.345
Regimens with LPV/r vs regimens without LPV/r 1.32 B0.001
Regimens with EFV
a vs regimens without EFV 1.04 0.496
Regimens with ATV / r vs regimens without ATV / r 0.99 0.993
EFV/FTC/TDF fixed-dose regimen vs all other regimens 0.39 B0.001
Age (in 5-year increments) 1.01 0.338
Male vs female 0.84 0.005
Region
Northeast vs South 1.01 0.891
Midwest vs South 0.85 0.027
West vs South 0.69 B0.001
Charlson Comorbidity Index
b 0.84 B0.001
Substance use disorder 1.30 B0.001
Year of indexdate
2003 vs 2007 1.66 B0.001
2004 vs 2007 1.88 B0.001
2005 vs 2007 1.44 B0.001
2006 vs 2007 1.34 0.002
aExcludes use of the EFV/TDF/FTC fixed-dose regimen.
bCharlson Comorbidity Index, a weighted index in which a higher score indicates a greater burden of comorbid disease.
Abbreviations: ATV, atazanavir; EFV, efavirenz; FDC, fixed-dose combination; FTC, emtricitabine; LPV, lopinavir; NNRTI, nonnucleoside
reverse transcriptase inhibitor; PI, protease inhibitor; r, ritonavir; TDF, tenofovir disoproxil fumarate.
Table 4. Multivariate risk of discontinuation of speciﬁc
regimens vs EFV/FTC/TDF ﬁxed-dose regimen (n1261,
including n316 on EFV/FTC/TDF ﬁxed-dose regimen).
Regimen Hazard ratio
a p-value
LPV/rAZT/3TC (n127) 2.33 B0.001
LPV/rTDF/FTC (n104) 2.03 B0.001
EFVAZT/3TC (n279) 1.83 B0.001
ATV/rTDF/FTC (n125) 1.19 0.217
EFVTDF/FTC
b (n310) 1.13 0.348
aCovariates included in the Coxproportional hazards regression
models were age, sex, region, Charlson Comorbidity Index score,
substance use, and year of indexdate.
bPatients who switched to EFV/FTC/TDF fixed-dose regimen
were censored.
Abbreviations: ATV, atazanavir; AZT, zidovudine; EFV,
efavirenz; FTC, emtricitabine; LPV, lopinavir; r, ritonavir; TDF,
tenofovir disoproxil fumarate; 3TC, lamivudine.
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comprising nearly one third of all known HIV-
infected patients in the United States (Board on
Health Promotion and Disease Prevention [HPDP],
2005). Our study found that factors driving ARV
treatment persistence in commercially insured pa-
tients were generally consistent with those seen in
published cohort studies of HIV-infected patients.
Consistent with the findings of existing studies in
other HIV populations (Braithwaite et al., 2007;
Domingo et al., 2008; Elzi et al., 2010; Willig et al.,
2008), regimen characteristics such as the utilization
of NNRTIs and the use of a fixed-dose, once-daily
ARV combination (EFV/FTC/TDF) were associated
with greater HIV treatment persistence. In our
analysis, treatment persistence was significantly long-
er and the risk of discontinuation was significantly
lower for patients on initial regimens containing
NNRTIs compared with PIs (pB0.001). In regimen-
level subanalyses, similar persistence was seen with
EFV- and ATV/r-based regimens, while use of LPV/r
in the indexARV regimen was associated with a
greater risk for discontinuation. The use of LPV/r in
the indexARV regimen may account for the reported
difference in PI vs NNRTI persistence and may be
related in part to the increased dosing frequency of
LPV/r (twice daily) vs ATV/r (once daily; Li et al.,
2005). The lower risk of regimen discontinuation
among patients using the single-tablet EFV/FTC/
TDF fixed-dose regimen is an outcome that has been
previously attributed to ease and convenience of use
(Willig et al., 2008). Prior to 2005, ARV regimens
were not as ‘‘patient friendly’’ as contemporary
regimens, which include more tolerable, co-formu-
lated NRTI backbones and once-daily dosing. Ease
and convenience of use may explain our finding that
the risk of regimen discontinuation was greater for
patients initiating ARV therapy in any year (2003
2006) prior to 2007 and that the risk of regimen
discontinuation decreased over the study period
(20032007). Further research is needed into the
reasons for differences in persistence between ARV
regimens and the reasons for and clinical outcomes
associated with extended persistence.
Our findings are in general agreement with avail-
able data on patient-level predictors of ARV therapy
durability in longitudinal analyses and in resource-
limited settings (Glass et al., 2009; Lazo et al., 2007;
Vo et al., 2008). Substance abuse is a well-known risk
factor for decreased adherence to ARV medication in
public assistance and homeless populations, and our
study confirms the extent of its negative impact on
privately insured individuals. The association be-
tween ARV-regimen persistence and geographical
location in the United States is intriguing and
warrants further investigation as to why the risk of
discontinuation is lower among privately insured
patients residing in the Midwest or West compared
with those residing in the South. In contrast to prior
studies, we found a lower risk of regimen disconti-
nuation (nonpersistence) associated with increased
Charlson comorbidity scores (Elzi et al., 2010). We
speculate that patients with a higher burden of
comorbidity may be more accustomed to taking
medications and, due to this familiarity, are more
likely to have increased persistence to an HIV
treatment regimen. These findings may highlight an
important challenge for clinicians, underscoring the
need to closely monitor ARV treatment persistence
among newly diagnosed HIV-infected patients who
are otherwise healthy and therefore ‘‘inexperienced’’
in long-term medication compliance. The strategies of
fixed-dose combinations and once-daily dosing that
have proven to increase persistence are important
assets to promulgating this behavior in newly HIV-
infected individuals.
Clinical studies evaluating persistence to ARV
therapy have shown varying results with regard to a
gender difference (Clark & Squires, 2005; Kempf
et al., 2009). We found a lower risk of ARV treatment
discontinuation in insured men compared with their
female counterparts. Although the reasons for a
lower risk of ARV-regimen discontinuation among
men than women are not entirely clear, several factors
exclusive to women may influence the risk of dis-
continuation such as contraception, pregnancy, and
breast feeding. A greater risk of ARV treatment
discontinuation among women in the Women’s
Interagency HIV Study was associated with high
HIV RNA levels and high depressive symptom scores
(Ahdieh-Grant et al., 2005). Further studies are
needed to assess the factors negatively impacting
persistence in women and men, particularly in insured
vs uninsured populations and in different geographi-
cal areas within the United States.
This study has a number of limitations. First,
insurance claims data are collected for administrative
purposes; they are not collected to address a specific
scientific question or purpose. Thus, this observa-
tional study allows us to identify associations but we
cannot attribute causality. Second, patients in this
study represent only those covered under health
plans participating in PharMetrics. While these
data are generally nationally representative, Phar-
Metrics data were not collected using a national
probability sample; therefore, care should be taken
in generalizing study results too broadly. Third, since
the data were obtained from a claims database,
patients defined as treatment-naive in this study may
have received ARV treatment prior to the pre-index
1160 T. Juday et al.period in this health plan or another health plan, as
treatment-naive status could not be confirmed by
individual chart review. However, this limitation
would have presumably affected all participants
equally. Furthermore, the number of ARV regimens
evaluated was limited due to a small number of
patients on specific regimens and the specific reasons
for treatment discontinuation were unknown.
Finally, the time period over which the study was
conducted (20032008) overlapped with a number of
therapeutic advances, including the introduction of
single-drug combination therapy following approval
of the EFV/FTC/TDF fixed-dose combination by
the US Food and Drug Administration in July 2006.
Conclusions
This study, the first of its kind to be conducted in a
commercially insured population of patients newly
treated for HIV with ARV therapy, demonstrated
that in HIV, treatment regimen persistence is longer
with NNRTI-based regimens than PI-based regimens.
Patient characteristics associated with a lower risk of
ARV treatment discontinuation included male sex,
presence of a higher burden of comorbid conditions,
and geographical region. Earlier year at indexdate
for regimen initiation and substance abuse were
associated with a greater risk of discontinuation. In
regimen-level subanalyses, LPV/r-based regimens
were associated with a greater risk of discontinuation
and ATV/r-based regimens showed no statistically
significant difference in risk of discontinuation when
compared with EFV/TDF/FTC, underscoring the
positive impact of once-daily dosing on long-term
treatment persistence.
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